NEW YORK, February 18, 2010 /PRNewswire-FirstCall/ -- SPO Medical Inc.
(OTC: SPOM), a leading developer of biosensor and microprocessor technologies
for use in portable monitoring devices, today announced it has been granted a
new and innovative baby monitoring patent relating to a non-invasive device
or system for monitoring and measuring the heart rate of a baby to activate
an alarm when the level falls outside a predetermined range. This issuance by
the United States Patent and Trademark Office (Patent # 7,650,176) brings the
Company's intellectual property (IP) portfolio to a total of twelve patents.
This latest patent, developed by the SPO Medical engineering team, increases
the Company's technological competitive edge in providing an innovative, high
performance solution for a market application applicable to most family homes.

This new patent focuses on commercial applications relating to the
implementation of reflectance pulse oximetry for monitoring babies and
infants particularly for ages up to 12 months. During their first year,
babies have increased susceptibility to breathing disturbances and
respiratory ailments which could lead to physiological distress. Early
detection of a respiratory ailment could provide the time to administer aid
necessary to prevent further deterioration of a baby's wellness. Many types
of consumer baby monitors are currently available but most do not give the
advance warning necessary for the caregivers to administer aid. In addition,
certain baby movement monitors are known to have a high level of "false
alarms" as they have no way to distinguish between the lapses in breathing,
which can be normal for a baby, and respiratory distress. This could result
in increased anxiety for the caregivers or cause them to ignore a signal
after responding repeatedly to false alarms. The new patent granted to SPO
specifically addresses this concern by providing a pro-active solution
through a real-time baby monitoring application.

Michael Braunold, President and Chief Executive Officer of SPO Medical
commented: "The granting of this innovative patent could have a major impact
on the baby monitoring market - it enables the commercialization of a
pro-active monitoring device that can help safeguard a baby during those
first-year critical months especially when parental or caregiver anxiety is
potentially high. With over 8 million births annually in the USA and Western
Europe alone, our objective is to make available this unique technology to
client corporations who have an interest in commercializing and distributing
a product which delivers parental reassurance attributes with real-time
monitoring of babies particularly while they are sleeping."

The Company has established a dedicated web site relating to this
homecare application; it can be viewed at http://www.spobaby.com along with a
video demonstration of the proposed commercial unit and a facility for making
additional enquires to the Company into this innovative product opportunity.

About SPO Medical:

SPO Medical (OTC: SPOM) a leading developer of biosensor and
microprocessor technologies for use in portable monitoring devices to capture
life-saving and life-enhancing information within four key markets: medical
care; home and remote-care; sports and wellness; and safety and security. Its
patented technology uses information gathered from the reflectance of light
on the human blood stream, in a non-invasive manner, to monitor key vital
signs. The Company licenses its technologies to appropriate client
corporations for commercialization and distribution. For more information,
visit http://www.spomedical.com and http://www.spobaby.com.

Forward Looking Statements:

This press release contains forward-looking statements that involve
substantial uncertainties and risks. These forward-looking statements are
based upon our current expectations, estimates and projections about our
business and our industry, and that reflect our beliefs and assumptions based
upon information available to us at the date of this release. We caution
readers that forward-looking statements are predictions based on our current
expectations about future events. These forward-looking statements are not
guarantees of future performance and are subject to risks, uncertainties and
assumptions that are difficult to predict. Our actual results, performance or
achievements could differ materially from those expressed or implied by the
forward-looking statements as a result of a number of factors, including but
not limited to, patent protection for our products and technologies, market
acceptance of our products and new product applications, product performance,
size of prospective markets, revenues assessments, changes in economic
conditions generally and the medical devices market specifically, changes in
technology, legislative or regulatory changes that affect us, the sufficiency
and availability of working capital, the introduction of competing products,
changes in our operating strategy or development plans and the risks and
uncertainties discussed under the heading "Risk Factors" in Item 1 of our
Annual Report on Form 10-K for the fiscal year ended December 31, 2008. We
undertake no obligation to revise or update any forward-looking statement for
any reason.

(Date:8/7/2017)... GAITHERSBURG, Md. , Aug. 7, 2017 /PRNewswire/ ... for healthcare member acquisition, retention, and engagement, announced ... Director of Strategy and Product Development, effective as ... strategic consulting and technology implementation strategy for our ... years of experience in consulting and business analytics ...

(Date:8/7/2017)... 7, 2017 Endo International plc (NASDAQ: ... resolve virtually all known U.S. mesh product liability claims ... the known remaining U.S. claims at reasonable values. Under ... the fourth quarter of 2017 and continuing through the ... quarter 2017 results, the Company intends to increase its ...

(Date:8/2/2017)... , Aug. 2, 2017 Fenita ... Who as a Pinnacle Lifetime Professional in the ... Account Manager at Turing Pharmaceuticals, AG. Her skills ... and relationship building. ... than 25 years of experience as a highly ...

(Date:8/17/2017)... ... August 17, 2017 , ... CareAcademy, ... that it has raised $1.675 M in seed funding to further expand its ... and Techstars Venture Capital Fund are the company’s primary investors. , ...

(Date:8/17/2017)... ... , ... Centrifugation is more than just spinning. Like a car in our ... do without. And just like a car, there are a few points to consider ... will learn about the most important safety aspects while using a centrifuge, as well ...

(Date:8/16/2017)... ... , ... The next Patient Care Academy at Kalamazoo Valley Community College begins ... the seven-week long Patient Care Academy are eligible to take the State of Michigan ... CNA in Kalamazoo is $24,428.* , As a CNA, one is equipped for employment ...

(Date:8/16/2017)... ... August 16, 2017 , ... The Data Council, the leading ... was acquired by Advantage Solutions. The Data Council’s IX-ONE platform is the ... industry’s leading suppliers, brokers, distributors and retailers. The Data Council will become a ...